http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103074421-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_567173f25ed8e9fdc74286a1894b1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c653e5afc8cf8ef1ed45f33455f5abc |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2012-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd5becdda3fb5bd77b5d21d699ec1e03 |
| publicationDate | 2013-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103074421-A |
| titleOfInvention | Vinblastine antitumor drug sensitivity detection technology |
| abstract | The invention discloses a vinblastine antitumor drug sensitivity detection technology. The vinblastine antitumor drug sensitivity detection technology belongs to the field of the molecular biological technology. The vinblastine antitumor drug sensitivity detection technology adopts primers, a probe and a kit. The kit comprises a PCR amplification reagent set, a SAP enzyme reagent set, and an iPLEX reagent set. The PCR amplification reagent set comprises a PCR buffer solution, MgCl2, a dNTP mixed solution, a HotstarTaq enzyme, pure water, upstream primers shown in the formulas of SEQ ID No. 1-3, and downstream primers shown in the formulas of SEQ ID No. 4-6. The SAP enzyme reagent set comprises a SAP buffer solution, a SAP enzyme and pure water. The iPLEX reagent set comprises an iPLEX buffer solution, a ddNTP mixed solution, an iPLEX polymerase, pure water, and single-base extension primers shown in the formulas of SEQ ID No. 7-9. Through the kit, the DNA of a cancer patient is extracted and treated; through a flight mass spectrum method, a biomarker in a detection primer amplified fragment is detected; and based on the detection result, vinblastine drug sensitivity of cancer patients is evaluated. The vinblastine antitumor drug sensitivity detection technology has the advantages of accurate result, high sensitivity, fast and simple processes, and high flux. |
| priorityDate | 2012-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.